Kannalife Sciences, a subsidiary of Neuropathix, Inc., was awarded a $2.97 million grant from the National Institutes of Health’s National Institute of Neurological Disorders and Stroke. John George covered the funding in the Philadelphia Business Journal.

Kannalife is housed at The Pennsylvania Biotechnology Center of Bucks County, as is its parent.

The three-year grant is funded through the NIH HEAL (Helping End Addiction Long-term) initiative to develop therapies and technologies directed at enhanced pain management.

Kannalife plans to use the proceeds to advance its development of a new drug candidate intended to ease neuropathic pain. The company is developing the therapy in a partnership with researchers at Temple University’s Lewis Katz School of Medicine.

“Chemotherapy-induced peripheral neuropathy is a real problem worldwide and a window into what real unmet needs are in treating chronic and neuropathic pain, as well as reducing the use of opioids [to treat neuropathy] and many other inflammatory pain related diseases and disorders,” said Dean Petkanas, CEO of Neuropathix.

“These critical resources will allow us to do the necessary research for a potential future investigation new drug filing with the FDA,” he concluded.

More on this story is at the Philadelphia Business Journal.